Olanow CW - Search Results

1

Neuroprotective agents in Parkinson's disease: clinical evidence and caveats.

Hälbig TD, Tse W, Olanow CW. Hälbig TD, et al. Among authors: olanow cw. Neurol Clin. 2004 Oct;22(3 Suppl):S1-S17. doi: 10.1016/j.ncl.2004.07.002. Neurol Clin. 2004. PMID: 15501359 Review. No abstract available.

2

The role of dopamine agonists in the treatment of early Parkinson's disease.

Olanow CW. Olanow CW. Neurology. 2002 Feb 26;58(4 Suppl 1):S33-41. doi: 10.1212/wnl.58.suppl_1.s33. Neurology. 2002. PMID: 11909983 Review.

3

Sleepiness in Parkinson's disease: a controlled study.

Brodsky MA, Godbold J, Roth T, Olanow CW. Brodsky MA, et al. Among authors: olanow cw. Mov Disord. 2003 Jun;18(6):668-72. doi: 10.1002/mds.10429. Mov Disord. 2003. PMID: 12784270

4

Dietary vitamin E and Parkinson's disease: something to chew on.

Olanow CW. Olanow CW. Lancet Neurol. 2003 Feb;2(2):74. doi: 10.1016/s1474-4422(03)00300-4. Lancet Neurol. 2003. PMID: 12849259 No abstract available.

5

COMT inhibitors in Parkinson's disease: can they prevent and/or reverse levodopa-induced motor complications?

Olanow CW, Stocchi F. Olanow CW, et al. Neurology. 2004 Jan 13;62(1 Suppl 1):S72-81. doi: 10.1212/wnl.62.1_suppl_1.s72. Neurology. 2004. PMID: 14718683 Review.

6

The scientific basis for the current treatment of Parkinson's disease.

Olanow CW. Olanow CW. Annu Rev Med. 2004;55:41-60. doi: 10.1146/annurev.med.55.091902.104422. Annu Rev Med. 2004. PMID: 14746509 Review.

7

Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease.

McNaught KS, Perl DP, Brownell AL, Olanow CW. McNaught KS, et al. Among authors: olanow cw. Ann Neurol. 2004 Jul;56(1):149-62. doi: 10.1002/ana.20186. Ann Neurol. 2004. PMID: 15236415

8

Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study).

Olanow CW, Damier P, Goetz CG, Mueller T, Nutt J, Rascol O, Serbanescu A, Deckers F, Russ H. Olanow CW, et al. Clin Neuropharmacol. 2004 Mar-Apr;27(2):58-62. doi: 10.1097/00002826-200403000-00003. Clin Neuropharmacol. 2004. PMID: 15252265 Clinical Trial. No abstract available.

9

Unilateral stimulation of the subthalamic nucleus in Parkinson disease: a double-blind 12-month evaluation study.

Germano IM, Gracies JM, Weisz DJ, Tse W, Koller WC, Olanow CW. Germano IM, et al. Among authors: olanow cw. J Neurosurg. 2004 Jul;101(1):36-42. doi: 10.3171/jns.2004.101.1.0036. J Neurosurg. 2004. PMID: 15255249 Clinical Trial.

10

Movement disorders and AIDS: a review.

Tse W, Cersosimo MG, Gracies JM, Morgello S, Olanow CW, Koller W. Tse W, et al. Among authors: olanow cw. Parkinsonism Relat Disord. 2004 Aug;10(6):323-34. doi: 10.1016/j.parkreldis.2004.03.001. Parkinsonism Relat Disord. 2004. PMID: 15261874 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

351 results

Search Page

Filters